What Is Tirzepatide?

Tirzepatide entered the public conversation as “the other shot”—the dual-agonist medicine that, in obesity trials, produced some of the largest average weight losses ever seen with a weekly injection. People ask how it differs from semaglutide, whether Mounjaro and Zepbound are the same thing, and whether the sleep-apnea approval changes who should consider it. This guide sticks to peer-reviewed trials and FDA labeling.

For the wider class, read what is a GLP-1 medication?. For the single-agonist comparator, see what is semaglutide?.

Educational only. This is not medical advice. Do not start, stop or change any medication without guidance from a licensed clinician who knows your history.

What is tirzepatide, in one paragraph?

Tirzepatide is a once-weekly injectable peptide that activates two nutrient-stimulated hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). That dual action is why scientists call it a dual GIP/GLP-1 receptor agonist rather than a pure GLP-1 drug. Like other incretin-based medicines, it helps regulate blood sugar, slows stomach emptying and reduces appetite, so most people eat less. In everyday talk it is often grouped with “GLP-1s”; that shorthand is useful as long as you remember the extra GIP pathway.

How does tirzepatide work?

Your gut releases several hormones after you eat. GLP-1 and GIP are two of them. Cleveland Clinic notes that dual GLP-1/GIP agonists are a related class to classic GLP-1 agonists, with tirzepatide as the marketed example.

According to the SURMOUNT-1 investigators and earlier pharmacology work they cite:

• Affinity for the GIP receptor is similar to native GIP.
• Affinity for the GLP-1 receptor is weaker than native GLP-1—but still clinically meaningful.
• In animal models, combining both pathways produced greater weight reduction than GLP-1 agonism alone.

In people, the lived experience looks familiar to anyone who has tried a GLP-1: earlier fullness, fewer large meals, and often less interest in grazing. Educational explainers—such as the NEJM summary video Once-Weekly Tirzepatide for Obesity and clinician pharmacology walk-throughs like Tirzepatide: How Does It Work for Weight Loss?—emphasize the same mechanism-to-practice link: appetite and intake drive most of the scale change.

NIDDK describes tirzepatide (Zepbound) as mimicking GIP and GLP-1 “to target areas of the brain that regulate appetite and food intake.”

Brand names: Mounjaro vs Zepbound

Product	Active ingredient	Form	Main FDA-approved use (US)
Mounjaro	Tirzepatide	Weekly injection	Type 2 diabetes
Zepbound	Tirzepatide	Weekly injection (pen or vial strengths)	Chronic weight management in adults; moderate-to-severe OSA in adults with obesity

Same molecule, different labels. Prescribing Mounjaro only for weight loss is off-label—legal in some clinical situations, but something the NIH says you should feel comfortable asking about. For the full 2026 list of weight-management approvals, see which GLP-1s are FDA-approved for weight loss.

The current Zepbound label also states that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.

Who is tirzepatide for?

For weight management, NIDDK lists Zepbound for adults with obesity or overweight plus weight-related conditions, used with a reduced-calorie diet and increased physical activity. Typical BMI thresholds clinicians use are 30 or more, or 27 or more with a weight-related condition—same framework as other chronic weight-management medicines.

Unlike Wegovy (semaglutide), NIDDK’s table does not list Zepbound for adolescents; pediatric use, if any, is a clinician-and-label question outside the adult overview here.

Sleep apnea indication

In December 2024, FDA approved Zepbound as the first prescription medicine specifically for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, still alongside diet and activity changes. That approval rested on the SURMOUNT-OSA phase 3 program.

Who should not use it

Labels contraindicate tirzepatide in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, reflecting the class boxed warning about thyroid C-cell tumors in rodents. NIH guidance also says weight-loss medicines should not be used during pregnancy or when planning pregnancy, and are not recommended while breastfeeding. Pancreatitis history, gallbladder disease, severe GI disease, kidney issues and diabetic eye disease all belong in the pre-treatment conversation.

What do the major trials show?

SURMOUNT-1: weight loss without diabetes

Published in NEJM in 2022, SURMOUNT-1 randomized 2,539 adults without diabetes (BMI ≥30, or ≥27 with a weight-related complication) to tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, including up to 20 weeks of dose escalation, plus lifestyle counseling.

Mean percentage weight change at week 72 (treatment-regimen estimand):

Dose	Mean weight change	vs placebo (percentage points)
5 mg	−15.0%	−11.9
10 mg	−19.5%	−16.4
15 mg	−20.9%	−17.8
Placebo	−3.1%	—

Share losing at least 5%: about 85% / 89% / 91% on 5 / 10 / 15 mg vs 35% on placebo.

Share losing at least 20%: about 30% / 50% / 57% on 5 / 10 / 15 mg vs 3% on placebo.

Share losing at least 25% (exploratory): about 15% / 32% / 36% vs 1.5% on placebo.

Waist circumference, blood pressure, lipids, fasting insulin and physical-function scores improved more with tirzepatide. Among participants with prediabetes at baseline, 95.3% on tirzepatide reverted to normoglycemia by week 72, versus 61.9% on placebo. In a DXA subgroup, total fat mass fell more than lean mass, improving body-composition ratios.

A peer-reviewed NEJM article and the journal’s short video summary made these figures widely accessible to clinicians and patients alike.

SURMOUNT-OSA: breathing disruptions

The SURMOUNT-OSA trials tested maximum tolerated tirzepatide (10 or 15 mg) for 52 weeks in adults with obesity and moderate-to-severe OSA, with and without ongoing PAP therapy. According to Lilly’s FDA approval announcement summarizing the program:

• Adults not on PAP: about 25 fewer breathing disruptions per hour with tirzepatide vs 5 with placebo.
• Adults on PAP: about 29 fewer vs 6 with placebo.
• Remission or mild, non-symptomatic OSA at one year: 42% (tirzepatide without PAP context as reported) and 50% (tirzepatide with PAP) versus 16% and 14% on placebo, respectively.

Those results support Zepbound’s OSA indication—but they do not mean everyone with snoring should start an injection. Diagnosis, PAP decisions and medication choice remain clinical.

How is treatment usually started?

Zepbound labeling describes a step-up schedule: treatment typically begins at a low weekly dose (labels describe starting at 2.5 mg weekly for four weeks) and increases in steps toward a maintenance dose. For OSA, the labeled maintenance doses highlighted in approval materials are 10 mg or 15 mg once weekly; the maximum recommended dose is 15 mg weekly. Exact steps, timing and whether to pause an increase belong to your clinician and the current label—not to a blog or a social feed.

On X, people often ask which pen strength “works fastest.” Faster is not the goal. Tolerability and adherence matter more than racing to the top row of the chart.

Common side effects and serious risks

Common (especially during escalation)

In SURMOUNT-1, gastrointestinal events were the most frequent, mostly mild to moderate, and clustered during dose escalation:

Event (approximate rates from trial table)	5 mg	10 mg	15 mg	Placebo
Nausea	24.6%	33.3%	31.0%	9.5%
Diarrhea	18.7%	21.2%	23.0%	7.3%
Constipation	16.8%	17.1%	11.7%	5.8%
Vomiting	8.3%	10.7%	12.2%	1.7%

Adverse events led to discontinuation in 4.3% / 7.1% / 6.2% on 5 / 10 / 15 mg versus 2.6% on placebo.

For food strategies and when to call a clinician, see GLP-1 nausea and the managing side effects guide.

Less common but important

• Gallbladder disease: Cholecystitis was reported more often with tirzepatide than placebo in SURMOUNT-1, though absolute rates were low (≤0.6% for some cholecystitis terms). Rapid weight loss itself raises gallstone risk.
• Pancreatitis: Adjudication-confirmed cases were rare and appeared across groups including placebo in SURMOUNT-1; severe abdominal pain still warrants urgent evaluation.
• Hypoglycemia: Low blood sugar under 54 mg/dL was uncommon but higher with tirzepatide than placebo in people without diabetes; risk rises if combined with insulin or sulfonylureas in diabetes care.
• Kidney injury: Watch hydration if vomiting or diarrhea is severe.
• Thyroid C-cell tumor warning: Same class boxed warning and MTC/MEN 2 restriction as other incretin injectables for obesity.

Tirzepatide vs semaglutide (brief)

Feature	Tirzepatide	Semaglutide
Receptors	GIP + GLP-1	GLP-1 only
Weight brands	Zepbound	Wegovy (injection, HD, pill)
Diabetes brands	Mounjaro	Ozempic / Rybelsus
Landmark obesity trial averages	Up to −20.9% at 15 mg / 72 wks (SURMOUNT-1)	−14.9% at 2.4 mg / 68 wks (STEP 1)
Extra labels of note	OSA (adults with obesity)	Heart-risk reduction (SELECT); MASH (accelerated); oral and HD options

Cross-trial comparisons are imperfect: populations, durations and estimands differ. A clinician will weigh your heart history, sleep apnea, diabetes status, side-effect tolerance, insurance and preference for injection versus pill. Dig deeper in the semaglutide vs tirzepatide guide and what is semaglutide?.

Cost, access and compounded products

List prices, savings cards and employer coverage vary widely. Manufacturer self-pay programs for brand products have shifted the cash landscape since 2024–2025, but eligibility rules matter. Start with our GLP-1 cost guide; for the semaglutide cash path people often compare against, see semaglutide cost without insurance.

The FDA warns that compounded tirzepatide is not FDA-approved and has not been reviewed for safety, effectiveness or quality before marketing. Dosing errors and quality concerns have been documented with compounded incretins generally. “Research chemical” vials sold online are not a substitute for an FDA-approved pen or vial from a licensed pharmacy.

What the first weeks usually feel like

Public questions about tirzepatide—on X and elsewhere—often collapse into: “Is this the T-drug my doctor mentioned?”, “Zepbound or Mounjaro?”, and “Will I lose as much as the trial averages?” Those are fair questions. The answers are usually: ask which product and indication were prescribed; they are not interchangeable labels; and averages are not promises.

Early practical patterns that align with SURMOUNT-1:

• GI symptoms peak during escalation. Nausea, diarrhea, constipation and vomiting were more common than placebo and mostly mild to moderate. Many people feel better once they stay on a stable dose.
• Appetite suppression can be strong. Skipping meals for long stretches often backfires (worse nausea, low energy). Small, planned, protein-forward intakes help.
• Hair shedding and fatigue show up in patient communities after rapid loss; treat them as signals to review calories, protein, iron status and sleep with a clinician—not as proof the drug is “toxic.”
• Injection technique matters. Pens and single-dose vials both exist for Zepbound strengths; whoever prescribes should also teach administration and storage.

Use the first 30 days guide as a checklist alongside your clinician’s instructions.

Cardiometabolic changes beyond the scale

SURMOUNT-1 was not only a weight trial. Compared with placebo, tirzepatide improved waist circumference, systolic and diastolic blood pressure, triglycerides, non-HDL cholesterol, HDL cholesterol and fasting insulin. Physical-function scores on the SF-36 also rose more with treatment. Those shifts help explain why obesity guidelines treat substantial weight reduction as a medical intervention—not a cosmetic project.

Still, baseline blood pressure and lipids in the trial population were relatively close to normal for many participants, which can make absolute changes look modest even when percentage improvements are meaningful. Your personal labs may move more or less.

Dual agonist does not mean “automatically better for everyone”

Higher average weight loss in SURMOUNT-1 versus STEP 1 is real and clinically interesting. It does not automatically make tirzepatide the right first choice for every adult. Considerations that often matter in clinic:

• Cardiovascular disease without diabetes: Semaglutide 2.4 mg has a dedicated outcomes trial (SELECT) showing a 20% reduction in major cardiovascular events. Tirzepatide’s cardiovascular outcomes story continues to evolve in dedicated programs; ask your clinician what is current for your situation.
• Sleep apnea with obesity: Zepbound’s OSA indication is a differentiator when that diagnosis is front and center.
• Preference for a pill: Oral semaglutide (Wegovy pill) and other oral options exist in the broader class; tirzepatide for obesity remains injectable in the US as of this writing.
• Side-effect tolerance and cost: Individual GI sensitivity and insurance formularies frequently decide the winner.

For structured side-by-side reading, stay with the semaglutide vs tirzepatide guide.

Setting expectations for “trial-like” results

SURMOUNT-1 participants received regular lifestyle counseling aimed at a 500-calorie daily deficit and at least 150 minutes of weekly activity. About 86% completed the primary treatment period across the study, with higher completion in tirzepatide arms than placebo. Real life includes travel, stress eating, coverage gaps and dose pauses. Expect meaningful benefit when the medicine is taken as prescribed and paired with habits—not a carbon copy of the group mean.

If weight loss is under 5% after a reasonable period on a full tolerated maintenance dose, NIDDK’s general guidance for weight-management medicines is to revisit the plan with your clinician (continue, adjust, switch or stop). That conversation belongs in clinic, with your actual trajectory in hand.

What happens if you stop?

NIDDK notes that people usually regain some weight after stopping a weight-management medication. Keeping nutrition and activity habits may reduce how much returns. Obesity is chronic; duration of therapy is an individualized decision based on benefit, side effects and goals.

Nutrition while appetite is low

Large losses include some lean mass. SURMOUNT-1’s DXA subgroup showed fat mass falling more than lean mass, but absolute lean mass still declined. Prioritizing protein and resistance training is the same counseling point you will hear for other GLP-1–based drugs. Practical detail lives in how much protein you need on a GLP-1 and the high-protein eating guide.

Questions worth bringing to your clinician

1. Am I a candidate for Zepbound based on BMI, conditions and contraindications?
2. Does my sleep apnea change whether tirzepatide is a first choice?
3. How will we escalate the dose if nausea shows up?
4. Should I use a pen or vial presentation, and who teaches injection technique?
5. How will we protect muscle and protein intake?
6. What will my plan cost with insurance or cash programs?
7. If I am already on semaglutide, what would switching look like for me?

The bottom line

Tirzepatide is a dual GIP/GLP-1 receptor agonist that, in SURMOUNT-1, produced average weight losses of about 15% to 21% over 72 weeks at approved dose levels—among the largest effects in obesity pharmacotherapy trials—while also gaining an FDA indication for moderate-to-severe OSA in adults with obesity. It is not a pure GLP-1 drug, it is not the same product as Mounjaro when the label says Zepbound, and it still requires medical supervision, gradual titration and realistic expectations about side effects and weight maintenance.

Continue in our tirzepatide hub, compare options in the semaglutide vs tirzepatide guide, or read what is semaglutide? side by side.